Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
Open Access
- 8 September 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 324 (10), 951-960
- https://doi.org/10.1001/jama.2020.15543
Abstract
Coronavirus disease 2019 (COVID-19) is an emerging respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that had infected more than 16 million individuals and caused more than 656 000 deaths worldwide by July 29, 2020.1 A safe and effective vaccine against COVID-19 is urgently needed.Keywords
This publication has 31 references indexed in Scilit:
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences of the United States of America, 2020
- Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- A Case of 2019 Novel Coronavirus in a Pregnant Woman With Preterm DeliveryClinical Infectious Diseases, 2020
- Key steps in vaccine developmentAnnals of Allergy, Asthma & Immunology, 2020
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialVaccine, 2008
- Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus VaccineAntiviral Therapy, 2007
- Disappearance of Antibodies to SARS-Associated Coronavirus after RecoveryThe New England Journal of Medicine, 2007
- RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE12American Journal of Epidemiology, 1969
- Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccinesJAMA, 1967
- Altered Reactivity to Measles VirusJAMA, 1967